KURA - Kura Oncology, Inc.
| Previous Close | 15.70 |
| Open | 15.84 |
| Bid | 0.00 x 1300 |
| Ask | 0.00 x 2200 |
| Day's Range | 15.65 - 16.35 |
| 52 Week Range | 12.30 - 21.42 |
| Volume | 376,778 |
| Avg. Volume | 261,351 |
| Market Cap | 716M |
| Beta (3Y Monthly) | 2.56 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.53 |
| Earnings Date | Nov 5, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.86 |
- Insider Monkey
Kura Oncology, Inc. (KURA): Hedge Funds Can’t Make Up Their Minds
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
- GlobeNewswire
Kura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma
– Tipifarnib demonstrates robust and durable activity as a monotherapy in advanced AITL, an aggressive form of T-cell lymphoma – – Enhanced activity (40% CR rate, 70% ORR).
- GlobeNewswire
Kura Oncology to Participate in Piper Jaffray Healthcare Conference
SAN DIEGO, Nov. 26, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the.
- TheStreet.com
Kura Oncology Requires Plenty of Patience by Investors
During the Lightning Round segment of Mad Money Friday night one caller inquired about Kura Oncology : "This has personalized cancer treatments and I like it for speculation," said Jim Cramer. In the daily bar chart of KURA, below, we can see that prices are showing us two trends. The daily On-Balance-Volume (OBV) line shows a decline into early October and then a rise.
- Thomson Reuters StreetEvents
Edited Transcript of KURA earnings conference call or presentation 5-Nov-19 9:30pm GMT
Q3 2019 Kura Oncology Inc Earnings Call
- GlobeNewswire
Kura Oncology to Present at Stifel Healthcare Conference
SAN DIEGO, Nov. 12, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the.
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Kura Oncology, Inc. (KURA)
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]
- GlobeNewswire
Kura Oncology Announces Upcoming Presentation at ASH Annual Meeting
SAN DIEGO, Nov. 06, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment.
- GlobeNewswire
Kura Oncology Reports Third Quarter 2019 Financial Results and Provides Corporate Update
– Updated data from Phase 2 trial of tipifarnib in HRAS mutant HNSCC support enrichment strategy in ongoing registration-directed trial – – Data from Phase 2 trial of.
- GlobeNewswire
Kura Oncology Appoints James Basta as Chief Legal Officer
Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of James Basta as Chief Legal Officer and Corporate Secretary. Mr. Basta will also serve as the Company’s Chief Compliance Officer. “We are privileged to have an executive of Jim’s caliber join our senior leadership team,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.
- GlobeNewswire
Kura Oncology to Report Third Quarter 2019 Financial Results
SAN DIEGO, Oct. 30, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment.
- GlobeNewswire
Kura Oncology Reports Durable Anti-Tumor Activity in Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer
Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today reported updated data from a Phase 2 clinical trial of its lead drug candidate, tipifarnib, that show durable anti-tumor activity as a single agent in heavily pretreated patients with HRAS mutant head and neck squamous cell carcinomas (HNSCC). As of the October 17, 2019 data cutoff date, a total of 21 HNSCC patients with high HRAS mutant variant allele frequency1 were enrolled in this Phase 2 trial (RUN-HN), of whom 18 were evaluable for efficacy. Ten of the 18 evaluable patients achieved a confirmed partial response (PR), as defined by standard RECIST criteria, for an objective response rate (ORR) of 56% (95% CI 0.31, 0.78).
- GlobeNewswire
Kura Oncology Data Selected for Oral Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
– Data from Phase 2 clinical trial of tipifarnib in HRAS mutant HNSCC selected for short-talk during Spotlight on Proffered Papers session on Tuesday, October 29th – –.
- GlobeNewswire
Kura Oncology Announces Upcoming Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
SAN DIEGO, Oct. 16, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment.
- GlobeNewswire
Kura Oncology Expands Board of Directors with Appointment of Diane Parks
Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of veteran commercial executive Diane Parks to its board of directors. Among her many achievements, Ms. Parks is credited with developing and executing the strategic plan for the launch of the novel CAR-T therapy Yescarta® and the marketing strategies for the blockbuster oncology drug Imbruvica®. “Diane is an accomplished executive with an impressive track record of driving profitable growth for large pharmaceutical and biotech companies,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.
- Thomson Reuters StreetEvents
Edited Transcript of KURA earnings conference call or presentation 1-Aug-19 8:30pm GMT
Q2 2019 Kura Oncology Inc Earnings Call
- GlobeNewswire
Kura Oncology Doses First Patient in Phase 1 Clinical Trial of Menin-MLL Inhibitor KO-539 in Acute Myeloid Leukemia
Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that the first patient has been dosed in a Phase 1 clinical trial of KO-539, the Company’s first-in-class inhibitor of the menin-mixed lineage leukemia (menin-MLL) interaction, in patients with relapsed or refractory acute myeloid leukemia (AML). “We believe KO-539 represents a differentiated approach to the treatment of patients with AML,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.
- GlobeNewswire
Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in HRAS Mutant Urothelial Carcinoma
Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced positive topline results from an investigator-sponsored Phase 2 trial of its lead drug candidate, tipifarnib, in patients with relapsed or refractory urothelial carcinomas that carry HRAS mutations. The ongoing, single-agent, single-arm trial is designed to enroll at least 18 patients, with a primary endpoint of progression-free survival (PFS) rate at 6 months.
- GlobeNewswire
Kura Oncology to Participate in Two Upcoming Investor Conferences
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.
- GlobeNewswire
Kura Oncology Announces Appointment of Kathleen Ford as Chief Operating Officer
Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of Kathleen Ford as Chief Operating Officer, effective immediately. Ms. Ford replaces John Farnam, who is stepping down from his position to pursue other interests. “We are very fortunate to have recruited an operations veteran with Kathy’s experience to Kura at a time when strategic prioritization and operational execution are among our highest priorities,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.
- GlobeNewswire
Kura Oncology to Present at Wedbush PacGrow Healthcare Conference
SAN DIEGO, Aug. 07, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the.
Motley FoolKura Oncology, Inc. (KURA) 2019 Q2 Earnings Call Transcript
KURA earnings call for the period ending June 30, 2019.
- GlobeNewswire
Kura Oncology to Report Second Quarter 2019 Financial Results
SAN DIEGO, July 25, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment.
- GlobeNewswire
Kura Oncology’s Menin-MLL Inhibitor KO-539 Receives Orphan Drug Designation from FDA for Treatment of Acute Myeloid Leukemia
Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the Company’s menin-mixed lineage leukemia (menin-MLL) inhibitor KO-539 for the treatment of acute myeloid leukemia (AML). “Orphan Drug Designation for AML represents a significant milestone in the development of KO-539,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.
- GlobeNewswire
Kura Oncology Expands Protection for Tipifarnib with New U.S. and European Patents
Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that the U.S. Patent and Trademark Office (USPTO) has issued and the European Patent Office has granted new patents further protecting the Company's lead drug candidate, tipifarnib, a potent and selective farnesyl transferase inhibitor. Tipifarnib is currently being studied in multiple solid tumor and hematologic indications, including a registration-directed clinical trial in HRAS mutant head and neck squamous cell carcinoma (HNSCC).
